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Rubella Immunization of Adult Females
Using HPV-77 DK-12 Live Attenuated Rubella Virus
Donald A. Romig, M.D.*, E . L , Quinn, M.D.*,
Frank Cox, M.D.* and Robert G. Brackett, Ph.D.**

This study demonstrates the serologic response as measured by the HAl test and the
side reactions of the HPV-77 DK-12 live rubella vaccine in a small group of adult
females. One hundred percent seroconversion was obtained using this vaccine.
The mean titers obtained in two separate time periods post-vaccination are higher
than those reported for several other rubella virus vaccines. A 66% occurrence of
joint symptomatology
was recorded post-vaccination with a mean duration of 11.6
days; 24% of women who received placebo reported joint complaints which had a
mean duration of 2.0 days. The difference between these two rates is somewhat
greater than that reported for other HPV-77 strain vaccines and the average
duration of these complaints is longer. The other symptoms
reported postvaccination seemed insignificant when comparing both the placebo and the
vaccine group. One woman became pregnant three months after vaccination and
was subsequently therapeutically aborted. At the time of therapeutic
abortion,
attempts were unsuccessful to recover rubella virus from the products of conception and cervical swabs.

The U.S. Public Health Service Advisory Committee on Immunization
Practices^ and the Committee on Infectious Diseases of the American Academy of Pediatrics currently recommend that boys and girls from the age
of one year through early elementary
school years be vaccinated against
rubella to eliminate the reservoir of
susceptible children and to create a
"herd immunity." In addition, this Advisory Committee has made specific
recommendations regarding live rubel-

la vaccination of the adult rubellasusceptible female in the childbearing
age. The study reported here was developed to show the serologic response,
side-effects, safety and patient acceptability of live rubella immunization
with HPV-77 DK-12 strain m a group
of susceptible adult females.
Materials and Methods
One hundred and eighty adult females of childbearing age were screened for rubella sero-reactivity. The subjects were from the staff, paramedical
personnel and families of Henry Ford
Hospital. Thirty-nine subjects (21.6%)
were sero-negative. Subsequently, in
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the summer of 1969, thirty of this
latter group volunteered to be inoculated with live attenuated rubella vaccine HPV-77 DK-12 in a reverse
double blind study. The age range of
the volunteers was from 14 to 27, with
an average age of 21 years. This strain
of rubella virus was safe and effective
in trials with children- and was licensed
for use in December of 1969.
Before vaccination, each subject was
interviewed and asked to afiirm that
she was not pregnant. Each vaccinee
was advised of the risk should she
become pregnant within 90 days after
vaccine administration and of the need
to use an acceptable contraceptive
measure—abstinence, oral contraceptive agents or an intrauterine device.
The possibility of reactions, including
transient arthritis, was explained to
each volunteer. At the time of admission to the study, none had signs or
symptoms of acute or chronic illness,
a history of allergy to dogs or dog
dander, or any known immunologic
defect. None had received gamma
globulin within the previous six weeks
or a live virus immunization in the
previous two weeks.
Subjects were asked to record daily
the presence or absence of the following: sore throat, cough, running nose,
burning or red eyes, earache, fever,
headache, loss of appetite, rash, swollen glands, and joint pain. These observations were tabulated daily usuig
a 70-day reporting form. The volunteers were advised that counseling and
physician evaluation were readily available during the study period.
Serum antibody titers were determined by modifications of the hemagglutination inhibition (HAI) method
of Stewart.3 H A I tests were performed

on all serum samples using the same
lot of antigen by laboratory personnel
who routinely perform several hundred
assays weekly.
Results
Sero-reactivity. Table 1 shows the
serologic response in 30 sero-negative
adult females after administration of
test vaccine. The number of subjects
and the specific H A I titers are indicated for the time periods shown. One
vaccine was not tested for serologic
response in the first time period but
was in the second. Another subject
withdrew from the study after her first
inoculation and bleeding. She refused
to complete the second half of the
study. She was tested in the first time
period but not the second. The geometric mean titers for the first and
second study periods were 1:137 and
1:232 respectively. Seroconversion in
this study was 100%.
The mean titers obtained with HPV77 DK-12 vaccine in this study are
higher than those reported for the
other licensed rubella vaccines. Hildebrandt and Weber-* found adult females
had a mean H A I titer of 1:498 between days 44 and 74 post-immunization with the Cendehill-51 strain. With
the same strain Halstead et aP reported
titers of 1:80 at 35 days. Lerman,"
studying the HPV-77 DE-5 strain in
adolescent girls and young women,
found a titer of 1:42 had developed 56
days after receipt of vaccine. Weibel
et al" reported titers of 1:53 in women
42 days after the duck embryo vaccine.
Studies with the RA 27/3 vaccine
strain recently licensed in England
showed seroconversion by either the
subcutaneous or intranasal inoculation;
however, titers lower than those in this
60
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Table I

SEROLOGIC RESPONSE IN 30 SERONEGATIVE ADULT
FEMALES GIVEN RUBELLA HPV-77 DK-12 VACCINE
Number Of Subjects
HAI Titer
<1:4
1:4
1:8
1:16
1:32
1:64
1:128
1:256
1:512
1:1024
TOTAL NO
SUBJECTS
GEOMETRIC
MEAN TITER

0 Days
(Prevaccination)

32-63 Days
after vaccination

70-120 Days
after vaccination
0
0
0

0
0
0

0
0
D
0
3
7
4
14
1

0

0

3
1

30

29

15

< 1:4

1:137

1:232

30
0
0
0
0

c

c
0

c
7
4

temporal relationship to vaccine administration except for joint complaints.
In comparing the subtotals obtained
after eliminating joint complaints, there
is no statistically significant difference
between the two groups in the number
of episodes of the various complaints.
Arthritis and/or Arthralgia. Table
I I I summarizes the reported joint
symptoms in the vaccinees and placebo
subjects. During the course of this
study, subjects who recorded joint
pains were not always seen by a physician. Accordingly, the tabulations were

study were recorded at 5 and 17
months post-vaccination.*
Side Reactions. The clinical findings
in the vaccine and placebo groups are
compared in Table I I . The total days
of observation (cf 1163 vs 1203) in
both groups are similar. Joint involvement was the only clinical finding
which was significantly different (p =
0.001 in the Chi square test). Although
the occurrence of headache is not significant statistically, a definite cluster of
headaches appeared in subjects receiving the live vaccine between day 11 and
14. No other clinical finding had a
61
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Table II
COMPARISON OF CLINICAL FINDING IN PLACEBO AND VACCINE SUBJECTS
Placebo
No. of
Average
Episodes
Duration
Sore Throat
Cough
Earache
Running Nose
Eyes Burning or Red
Fever
Headache
Appetite Loss
Rash
Swollen Glands
Subtotal
Joint Pain
(including Back)

Vaccine
No. of
Average
Episodes
Duration

12
6
3
8
2
2
22
5
3
4

2.66
2.66
1.0
4.25
1.0
1.5
1.47
2.4
2.33
1.5

15
10
1
10
4
8
27
6
2
6

2.33
4.1
1.0
4.5
2.75
2.25
2.03
3.16
2.5
3.16

67

2.1

89

2.79

r

2.8

31*

7.22

TOTAL
Day of Observation

1163

1203

*_P value = 0.001 by Chi square
made without attempts at delineating
arthritis from arthralgia.
Sixty-six percent of the vaccinees receiving HPV-77 DK-12 rubella vmis
experienced joint discomfort as compared to 24% of the placebo subjects.
These percentages include five individuals who experienced back pain
during the study period.
Table I I I compares the vaccine and
placebo groups as to time of onset and
duration of joint symptoms. The time
of onset in our study is similar to that

obtained by Weibel^ and Lerman et aF
using HPV-77 DE-5 vaccine. The
mean duration with the study vaccine
is greater than they report for the
HPV-77 DE-5 live rubella vaccine. If
one adjusts the time of onset of arthritic symptoms reported after natural
disease'' !" ^s "day after the onset of
rash" to compensate for the incubation
period, the mean time of onset approximates that found with the vaccine induced symptoms, 20.7 days. However,
the mean duration of 3.5 days^" and
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Table III
ARTHRITIS OR ARTHRALGIA IN 30 ADULT FEMALES
GIVEN RUBELLA VACCINE HPV-77 DK-12

Number with arthralgia or arthritis/
Number observed

Vaccine

Placebo

20/
30

7/
29*

Time of onset:
Range

12-31 days

1-54 days

Mean

20.7 days

22.5 days

Range

1-29 days

1-5 days

Mean

11.6 days

Duration:

2 days

*One subject withdrew from study and did not receive placebo.
joint involvement in eight individuals,
ie, 26.6% of the vaccinees. If back
discomfort is eliminated from these
tabulations, then 16 sites of involve-

9 days" is less than the 11.6 days which
we observed. The persistence of joint
discomfort with natural rubella is apparently quite variable, 1-7 days^" to
1-28 days* with the latter similar to
our finding of 1-29 days.
The sites of joint involvement are
shown in Table IV. Of the 20 subjects
who reported joint complaint, 12
(60%) did not specify location or
potential multiple sites of joint involvement. These 12 vaccinees were not
examined by one of the investigators,
so we can conclude little except to
suggest that duration and/or extent of
joint involvement was not significant
enough to warrant the attention of a
physician. However, the remainder of
the data shows 17 separate sites of

Table IV
SITES OF JOINT INVOLVEMENT IN 20
VACCINEES WITH RUBELLA ARTHRITIS OR ARTHRALGIA
Hand
Proximal interphalangeal
Fingers
Wrist
Foot
Metatarsophalangeal
Toes
Hip
Knee
Ankle
Back
Joint not specified
Total

63

?.
3
1
1
2
1
3
1
3
12
29
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ment were recorded in seven subjects.
Seven of the placebo subjects (24%)
also experienced joint symptoms as
seen in Table I I I . The mean duration
of joint symptoms in the placebo group
is much less than that in the vaccine
group. In naturally-occurring rubella
as described by Yanez,'-' there was no
documented involvement of the spine
or axial-skeleton. Neither did Thompson et al- find axial-skeletal involvement among 40 carefully studied
children with joint symptoms following
immunization with HPV-77 DK-12.
However, Smith and Guzowskai" reported 20% of their patients with
natural rubella exhibited spine discomfort, 8% of them experiencing
spinal stiffness. Because of this report,
back discomfort must be considered as
a possible clinical finding following
natural or vaccine induced rubella infection. The sites of joint involvement
in naturally-occurring rubella arthritis
are similar to those noted in this study,
the symptoms prepondering in the
small joints of the hands and feet.
Tenosynovitis, which has been reported by Thompson et al- and Yanez
et al,» did not appear to contribute to
the joint or musculo-skeletal symptoms
of this vaccine group. Since we recorded only one subject with wrist involvement during the study, tenosynovitis was not a prominent feature.
Significant joint involvement after
rubella vaccination has been reported
by several other investigators. The
evaluation by Halstead et al" has shown
that the Cendehill vaccine in adult
women produced very few joint symptoms. Other studies tend to support
thisfinding.**!' However, the HPV-77
DE-5 live rubella strain has been
shown to produce joint complaints in

39 to 43% of susceptible women vaccinated.*'** While minimal swelling was
noted in the fingers of one subject and
the knee of another, no significant effusions were observed as have been
reported with HPV-77 DE-5' and
Cendehill."
Complications
One of the vaccinees became pregnant three months after vaccination.
She was using an intrauterine device at
the time of conception. As fetal transmission of the vaccine virus has been
reported by other investigators,'- therapeutic abortion was performed 131
days after live rubella virus vaccine and
approximately 41 days after conception. The estimated day of conception
occurred at 90 days after vaccine administration. Two different laboratories
unsuccessfully attempted rubella virus
isolation from the decidual tissue and
cervical swabs obtained at the time of
therapeutic abortion.
Discussion
There is a lack of unanimity regarding mass immunization of prepubertal
children as an indirect approach to the
elimination of rubella virus risk to the
fetus. Critics of this approach have
been concerned with effectiveness of
the "herd immunity concept" in preventing rubella disease, reinfection of
vaccinees on exposure to wild virus,
spread of potentially teratogenic attenuated virus from child to pregnant
mother, and the duration of immunity, la-is
An alternative prophylactic approach is the direct immunization of
postpubertal females. The major concern here lies in the as yet incompletely
assessed risk of attenuated vaccine
virus infection of the fetus. Should the
64
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The hazard of reinfection occurring
in a pregnant woman with vaccine induced immunity is significant only if
viremia occurs. Data available to date
has failed to show that viremia occurs
during reinfection.-' However, virus
shedding from the pharynx of reinfected vaccinees has been reported to
occur but at a much reduced rate when
compared to natural infection.'^'^^

women be pregnant at the time of
vaccination or become pregnant within
one or two months, will the virus infect
and damage the fetus? Data on this
subject is still limited but Vaheri et alphas reported on the isolation of rubella
virus from uterine products at the time
of hysterectomy or curettage after rubella vaccine administration to pregnant women. Similarly Phillips et al"'
recently described the isolation of rubella virus from decidual tissue obtained at eight weeks of gestation approximately 37 days after vaccination.
Histological changes in the tissue were
described as similar to those seen in
gestational rubella.
Another concern regarding rubella
immunization, which applies to the
immunization of children as well as
women of childbearing potential, is the
matter of reinfection. Horstman et a l "
reported a reinfection rate of 80% in
Cendeh ill-vaccinated young adult males
exposed in an epidemic based on a
four-fold or greater increase in hemagglutination-inhibiting and complementfixing antibody. This she compares to
a 3.4% response in naturally immune
men in the same recruit population.
The evidence she presents indicates
that "reinfection rates are correlated
in a general way with H A I antibody
levels." This is supported by data from
Abrutyn et al-" in their 9-month follow-up on vaccinated children exposed
to natural challenge. They found reinfection rates of 11.6% for placebo
recipients, 13.1% for HPV-77 DE-5
vaccinees and 4.4% for HPV-77 DK12 vaccinees. They propose that reinfection occurred less frequently
among the HPV-77 DK-12 recipients
because of the generally higher titer
induced by this vaccine.

Conclusions
1. An attenuated live rubella virus
vaccine, HPV-77 DK-12, yielded
100% seroconversion and antibody
titers higher than reported for other
currently available rubella vaccines.
2. The clinical findings of joint involvement after vaccine administration
were significantly greater than after
placebo administration. The percentage
of subjects that experienced joint symptoms in this study was greater than that
reported with other currently available
rubella vaccines.
3. Prestudy counselling may have
conditioned some responses. However,
no subject regretted her participation
in the study. This positive response
despite the occurrence of joint symptomatology was gratifying.
4. Fetal transmission was not documented in one subject who became
pregnant three months after vaccine
administration.
5. The practice of immunizing women of childbearing potential is a matter
for serious consideration and must be
evaluated on an individual basis by
the physician and patient. Every effort
should be taken to insure against immunizing a pregnant woman or one
65

Romig, Quinn, Cox and Brackett
who may become pregnant within one
or two months of vaccination.
6. The higher incidence of joint discomfort with HPV-77 DK-12 vaccme
must be weighed against the potential
benefits of higher antibody titers
achieved with this strain.

Acknowledgment
We wish to thank Parke-Davis Research Laboratories for partial support
of the study by a research grant-in-aide,
and Mrs. Carole Fletcher and Miss
Judy Gouriey, research nurses, for
their part in the study.

REFERENCES
1. Rubella Virus Vaccine—Recommendation of the Advisory Committee on Immunization
Practices, U.S. Pubhc Health Service, Ann Intern Med 73:779-81, Nov 1970.
2. Thompson, G. R.; Ferreyra, A., and Brackett, R. G.: Acute arthritis complicating rubella
vaccination. Arthritis Rheum, in press.
3. Stewart, G. L., et al: Rubella-virus hemagglutination-inhibition test. New Eng J Med
276:554-7, 9 Mar 1967.
4. Hildebrandt, R. J. and Weber, J. M.: Immunization of young adult females with the
Cendehill strain of rubella vaccine, Amer J Obstet Gynec 107:645-7, 15 Jun 1970.
5. Halstead, S. B.; Char, D. F., and Diwan, A. R.: Evaluation of three rubella vaccines in
aduh women, JAMA 211:991-5, 9 Feb 1970.
6. Lerman, S. J., et al: Immunologic response, virus excretion and joint reactions with
rubella vaccine. A study of adolescent giris and young women given live attenuated
virus vaccine (HPV-77: DE-5), Ann Intern Med 74:67-73, Ian 1971.
7. Weibel, R. E., et al: Rubella vaccination in adult females. New Eng J Med 280-682-5
27 Mar 1969.
8. Ingalls, T. H., et al: Immunisation of school children with rubella (RA27/3) vaccine.
Intranasal and subcutaneous administration. Lancet 1:99-101, 17 Jan 1970.
9. Yanez, J. E., et al: Rubella arthritis, Ann Intern Med 64:772-7, Apr 1966.
10. Smith, D. and Guzowska, J.: Arthritis complicating rubella, Med J Aust 1:845-7, 25 Apr
1970.
11. Horstman, D. M.; Liebhaber, H., and Kohorn, E. I . : Post-partum vaccination of rubellasusceptible women. Lancet 2:1003-6, 14 Nov 1970.
12. Vaheri, A., et al: Transmission of attenuated rubella vaccines to the human fetus. A
prehminary report, Amer J Dis Chdd 118:243-6, 1969.
13. Lelane, D. E.; Newberg, N. R., and Beam, W. E., Jr.: Evaluation of rubella herd immunity
during an epidemic, JAMA 213:2236-9, 28 Sept 1970.
14. Horstmann, D. N., et al: Rubella: Reinfection of vaccinated and naturally immune persons
exposed in an epidemic. New Eng J Med 283:771-8, 8 Oct 1970.
15. Beasley, R. P.: Dilemmas presented by the attenuated rubella vaccines, Amer J Epidem
92:158-61, Sept 1970.
16. Leedom, I . M., et al: Important assumptions, extrapolations and established facts which
underiie the use of live rubella virus vaccines, Amer J Epidem 92:151-7, Sept 1970.
17. Enders, I . F.: Rubella vaccination, New Eng J Med 283:261-3, 30 Jul 1970.
18. Wilkins, J., et al: Reinfection with rubella virus despite live vaccine induced immunity:
Ria Trials of HPV-77 and HPV-80 live rubella virus vaccines and subsequent artificial
and natural challenge studies, Amer J Dis Child 118:275-94, Aug 1969.
19. Phillips, C. A., et al: Intrauterine rubella infection following immunization with rubella
vaccine, JAMA 213:624-5, 27 Jul 1970.
20. Abrutyn, E., et al: Rubella vaccine comparative study. Nine-month follow-up and serologic
response to natural challenge, Amer J Dis Child 120:129-33, 1970.
21. Davis, W. J., et al: A study of rubella immunity and resistance to infection JAMA
215:600-8, 25 Jan 1971.

66

T

